[1] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology,2016,64(1):73-84.
[2] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol,2017,67(4):862-873.
[3] Huang DQ, Singal AG, Kono Y, et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab,2022,34(7):969-977.
[4] Angulo P, Kleiner DE, Dam-Larsen S et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2015,149(2):389-397.e10.
[5] Kwan SY, Jiao J, Joon A, et al. Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease. Hepatology, 2022,75(4):955-967.
[6] Ley RE. Gut microbiota in 2015: Prevotella in the gut: choose carefully. Nat Rev Gastroenterol Hepatol,2016,13(2):69-70.
[7] Mayneris-Perxachs J, Castells-Nobau A, Arnoriaga-Rodríguez M, et al. Microbiota alterations in proline metabolism impact depression. Cell Metab, 2022,34(5):681-701.e10.
[8] Díaz LA, Fuentes-López E, Ayares G, et al. The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. Lancet Gastroenterol Hepatol, 2022,7(6):552-559.
[9] Lazarus JV, Mark HE, Villota-Rivas M, et al. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? J Hepatol,2022,76(4):771-780.
[10] Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract,2022,28(5):528-562.
[11] Duell PB, Welty FK, Miller M, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol,2022,42(6):e168-e185.
[12] 中华医学会内分泌学分会,中华医学会糖尿病学分会.中国成人2型糖尿病合并非酒精性脂肪性肝病管理专家共识.中华内分泌代谢杂志,2021,37(07):589-598.
[13] Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol,2021,6(11):903-913.
[14] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut, 2022,71(1):156-162.
[15] Zou ZY, Fan JG. Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease. J Hepatol,2020,73(1):214-216.
[16] Nonalcoholic steatohepatitis clinical research network. Hepatology, 2003,37(2):244. |
